SCHEMBL25657486

SCHEMBL25657486

CNC(CC(F)F)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 5/20 0.39
NAALAD2 Q9Y3Q0 4/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
THRB P10828 1/20 0.35
ALOX15 P16050 1/20 0.35
NFKB1 P19838 1/20 0.35
PTGS2 P35354 1/20 0.35
THPO P40225 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TGFBR1 P36897 2/20 0.32
ACE P12821 1/20 0.32
MME P08473 3/20 0.32
RIMKLA Q8IXN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13127847 0.81 KISS1R (0.31) ALDH1A1
SCHEMBL24633945 0.79 FOLH1 (0.34) FOLH1NAALAD2ALDH1A1MEN1LMNA
SCHEMBL31754331 0.79 FOLH1 (0.34) FOLH1NAALAD2ALDH1A1MEN1LMNA
SCHEMBL93452 0.78 ALDH1A1 (0.61) FOLH1NAALAD2ALDH1A1MEN1LMNA
SCHEMBL17881339 0.78 FOLH1 (0.40) FOLH1NAALAD2ALDH1A1MEN1LMNA
SCHEMBL93451 0.78 ALDH1A1 (0.61) FOLH1NAALAD2ALDH1A1MEN1LMNA
SCHEMBL93453 0.78 ALDH1A1 (0.61) FOLH1NAALAD2ALDH1A1MEN1LMNA
SCHEMBL31522775 0.77 POLB (0.35) FOLH1SMN1; SMN2MME
SCHEMBL25657484 0.77 POLB (0.35) FOLH1SMN1; SMN2MME
SCHEMBL18248103 0.77 GRN (0.37) FOLH1NAALAD2ALDH1A1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4309741-A1 CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-01-24 EP disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS FOLH1 3914/4885NAALAD2 2104/4885ALDH1A1 4838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.